2022
Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
Chan P, Yoon B, Colby D, Kroon E, Sacdalan C, Sriplienchan S, Pinyakorn S, Ananworanich J, Valcour V, Vasan S, Hsu D, Phanuphak N, Paul R, Spudich S. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2022, 76: e718-e726. PMID: 35687498, PMCID: PMC9907536, DOI: 10.1093/cid/ciac466.Peer-Reviewed Original ResearchConceptsAcute HIV-1 infectionT-cell countsDTG-based antiretroviral therapyAntiretroviral therapyDTG groupEFV groupWeek 96Week 24CD4/CD8 ratioNucleoside reverse transcriptase inhibitorHuman immunodeficiency virus type 1Immunodeficiency virus type 1Fiebig stages IPlasma viral suppressionAcute HIV infectionTreatment-naive individualsHIV-1 infectionPatient Health QuestionnaireReverse transcriptase inhibitorVirus type 1Greater incrementART regimensCD8 ratioViral suppressionHIV infection
2013
An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy
Dahl V, Gisslen M, Hagberg L, Peterson J, Shao W, Spudich S, Price RW, Palmer S. An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy. The Journal Of Infectious Diseases 2013, 209: 1618-1622. PMID: 24338353, PMCID: PMC3997583, DOI: 10.1093/infdis/jit805.Peer-Reviewed Original ResearchConceptsCentral nervous systemSuppressive therapyTreatment initiationNervous systemPlasma sequencesHIV Type 1 VariantsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Cerebrospinal fluid specimensType 1 variantsVirus type 1CSF sequencesViral persistenceHIV-1Cerebrospinal fluidFluid specimensTherapyType 1Virus replicationMajor causePlasma samplesCSFViral evolutionSubjectsLittle evidence
2009
Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection
Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. Journal Of Virology 2009, 84: 2395-2407. PMID: 20015984, PMCID: PMC2820937, DOI: 10.1128/jvi.01863-09.Peer-Reviewed Original ResearchConceptsHIV-1 populationsPrimary HIV-1 infectionCentral nervous systemHIV-1 infectionHIV-1 variantsDistinct HIV-1 populationsIndependent HIV-1 replicationHIV-1-infected individualsHuman immunodeficiency virus type 1Full-length env genesImmunodeficiency virus type 1HIV-1 transmissionSingle genome amplificationHIV-1 replicationHeteroduplex tracking assaysCourse of infectionSubset of subjectsVirus type 1Severe neurological diseaseClonal amplificationPeripheral bloodPrimary infectionCNS environmentCerebrospinal fluidNervous systemCompartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia
Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia. PLOS Pathogens 2009, 5: e1000395. PMID: 19390619, PMCID: PMC2668697, DOI: 10.1371/journal.ppat.1000395.Peer-Reviewed Original ResearchConceptsHIV-1-associated dementiaCentral nervous systemAntiretroviral therapyCerebrospinal fluidNeurological diseasesAsymptomatic subjectsHIV-1-associated neurological diseasePeripheral CD4 cell countViral replicationHuman immunodeficiency virus type 1HIV-1 associated dementiaViral decayImmunodeficiency virus type 1HIV-1 genetic variantsCNS drug penetrationRapid viral decayViral decay kineticsCD4 cell countDrug-resistant virusesHigh viral loadHIV-1 variantsVirus type 1Productive viral replicationHAD subjectsCSF pleocytosis